Top Stories
KV Pharmaceutical Announces Launch of Two Strengths of Generic Versions of Toprol-XL®
July 26, 2007 - KV Pharmaceutical Company (NYSE: KVa/KVb) announced today that it has begun shipment of its 100 mg and 200 mg strengths of metoprolol succinate extended release tablets. Based on the Company’s first-to-file status on its ANDA for these two strengths, KV anticipates being accorded the benefit of a 180-day generic exclusivity period for the marketing of these two dosage strengths. The Company also announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment in the Company’s favor in its patent litigation with AstraZeneca. The decision clears the way for the Company to market its metoprolol succinate extended-release tablets without interference from the AstraZeneca patents.
Recent Headlines
For additional press releases, go to
the press release archive.
|
|
The Press Releases shown in this section of the Web
site are presented for archival purposes only. The Press Releases are presented as they were
originally released. The Company makes no claim that the information contained in these materials
is currently accurate or is presented in a manner that would be appropriate for dissemination as
a press release at the present time. See
also KV
Pharmaceutical Company Web Site Terms of Use and Legal Restrictions and Product
Disclaimer.
|
